China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has entered into a strategic partnership with compatriot firm Bennu Biotherapeutics, a T-cell therapy specialist based in Shanghai. The collaboration focuses on the area of gene and cell therapies (GCTs), with Porton providing comprehensive CDMO services to Bennu. The agreement covers a range of services including plasmids, viruses, TIL, TCR-T, and Treg cells, among others. Financial details of the partnership were not disclosed.
About Suzhou Porton Biologics
Founded in 2018, Suzhou Porton Biologics has established itself as a leading end-to-end CGT CDMO service provider. The company’s platform covers a broad spectrum of therapeutic areas, including plasmids, cell therapies, gene therapies, oncolytic viruses, nucleic acid therapies, live bacterial therapies, and more. This comprehensive service offering positions Porton as a key player in the development and manufacturing of advanced therapies.
About Bennu Biotherapeutics
Bennu Biotherapeutics is a Shanghai-based specialist in T-cell therapies, focusing on the development of innovative cell therapies targeting tumor and autoimmune diseases. The partnership with Porton Biologics will enhance Bennu’s capabilities in bringing these therapies to market, leveraging Porton’s extensive experience and infrastructure in CDMO services.-Fineline Info & Tech
